Insider · CIK 0001199297

MITCHELL DEAN J

Reports to the SEC for 11 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001199297

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-23	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−22K sh	—	—	0
2026-09-23	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−23.6K sh	—	—	0
2026-09-23	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,000 sh	—	—	0
2026-09-23	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,000 sh	—	—	0
2026-09-23	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−24.3K sh	—	—	0
2026-09-23	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−13.4K sh	—	—	0
2026-09-23	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−28K sh	—	—	0
2026-09-23	TBPHTheravance Biopharma, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−91.2K sh	—	—	6,009
2026-09-23	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,000 sh	—	—	0
2026-09-23	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−6,000 sh	—	—	0
2026-09-23	TBPHTheravance Biopharma, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−6,009 sh	—	—	0
2026-06-12	TBPHTheravance Biopharma, Inc.A Award	Director	AAward	+6,009 sh	—	—	97,213
2026-06-12	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)A Award	Director	AAward	+13.4K sh	—	—	13,398
2026-06-10	PRAXPraxis Precision Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+648 sh	—	—	648
2026-06-10	PRAXPraxis Precision Medicines, Inc.A Award	Director	AAward	+1,371 sh	—	—	18,622
2025-09-24	PRAXPraxis Precision Medicines, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,932 sh	$14.36	+$27.7K	6,932
2025-09-24	PRAXPraxis Precision Medicines, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,932 sh	—	—	0
2025-09-24	PRAXPraxis Precision Medicines, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−8,566 sh	—	—	0
2025-09-24	PRAXPraxis Precision Medicines, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+1,753 sh	$44.04	+$77.2K	17,251
2025-09-24	PRAXPraxis Precision Medicines, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−1,753 sh	—	—	8,767
2025-09-24	PRAXPraxis Precision Medicines, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+8,566 sh	$44.25	+$379K	15,498
2025-06-26	PRAXPraxis Precision Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10.5K sh	—	—	10,520
2025-05-19	TBPHTheravance Biopharma, Inc.A Award	Director	AAward	+10.6K sh	—	—	91,204
2025-05-19	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)A Award	Director	AAward	+24.3K sh	—	—	24,258
2024-06-05	PRAXPraxis Precision Medicines, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+8,566 sh	—	—	8,566
2024-05-08	TBPHTheravance Biopharma, Inc. · Share Option (Right to Buy)A Award	Director	AAward	+23.6K sh	—	—	23,576
2024-05-08	TBPHTheravance Biopharma, Inc.A Award	Director	AAward	+10.5K sh	—	—	80,555
2024-04-03	Kinnate Biopharma Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−25K sh	—	—	0
2024-04-03	Kinnate Biopharma Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20.3K sh	—	—	0
2024-04-03	Kinnate Biopharma Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−20.3K sh	—	—	0
2024-04-03	Kinnate Biopharma Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−122K sh	—	—	0
2024-03-14	PGENPRECIGEN, INC.A Award	Director	AAward	+39.5K sh	$1.43	+$56.5K	503,183
2024-03-14	PGENPRECIGEN, INC. · Option to Purchase Common Stock (Right to Buy)A Award	Director	AAward	+102K sh	—	—	101,626
2024-03-14	PGENPRECIGEN, INC. · Restricted Stock UnitsA Award	Director	AAward	+87.4K sh	—	—	87,412
2024-03-09	PGENPRECIGEN, INC.M Exercise/Conversion	Director	MExercise/Conversion	+107K sh	—	—	463,673
2024-03-09	PGENPRECIGEN, INC. · Restricted Stock UnitsM Exercise/Conversion	Director	MExercise/Conversion	−107K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−44K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−18K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Deferred Share UnitD Disposition to Issuer	Director	DDisposition to Issuer	−143K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Restricted Stock UnitD Disposition to Issuer	Director	DDisposition to Issuer	−13.1K sh	—	—	0
2024-02-12	ImmunoGen, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−103K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−19.6K sh	—	—	0
2024-02-12	ImmunoGen, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−44K sh	—	—	0
2023-09-22	PGENPRECIGEN, INC.P Purchase	Director	PPurchase	+25K sh	$1.41	+$35.3K	356,836
2023-09-22	ImmunoGen, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$14.70	+$147K	103,000
2023-09-22	ImmunoGen, Inc.M Exercise/Conversion	Director	MExercise/Conversion	+10K sh	$14.70	+$147K	152,667
2023-09-22	ImmunoGen, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director	MExercise/Conversion	−10K sh	—	—	0
2023-06-14	ImmunoGen, Inc.Restricted Stock UnitA Award	Director	AAward	+13.1K sh	—	—	13,090

Recent filings

Accepted (ET)
Sep 244
MITCHELL DEAN J0001199297-26-000006
SEC(opens sec.gov)
Jun 164
MITCHELL DEAN J0001199297-26-000003
SEC(opens sec.gov)
Jun 124
MITCHELL DEAN J0001689548-26-000059
SEC(opens sec.gov)
Sep 254
MITCHELL DEAN J0001689548-25-000096
SEC(opens sec.gov)

Companies

Address

C/O THERAVANCE BIOPHARMA US, LLC 901 GATEWAY BLVD

SOUTH SAN FRANCISCO, CA, 94080